共 13 条
[1]
Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Zeltser R,Valle L,Tanck C,et al. Archives of Dermatology . 2001
[2]
Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Sfikakis PP,Theodossiadis PG,Katsiari CG,et al. The Lancet . 2001
[3]
Etanercept (Enbrel): update on therapeutic use. Spencer-Green G. Annals of the Rheumatic Diseases . 2000
[4]
Infliximab for refractory sarcoidosis. Baughman RP,Lower EE. Sarcoidosis Vasc Diffuse Lung Dis . 2001
[5]
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Chaudhari U,Romano P,Mulcahy LD,et al. The Lancet . 2001
[6]
Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Girolomoni G,Abeni D. Archives of Dermatology . 2001
[7]
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Mease PJ,Goffe BS,Metz J,et al. The Lancet . 2000
[8]
Remission of Behcet’s syndrome with tumour necrosis factor alpha blocking therapy. Goossens PH,Verburg RJ,Breedveld FC. Annals of the Rheumatic Diseases . 2001
[9]
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet’s disease: a case report. Hassard PV,Binder SW,Nelson V,et al. Gastroenterology . 2001
[10]
Infliximab in patients with primary Sjogren’s syndrome: a pilot study. Steinfeld SD,Demols P,Salmon I,et al. Arthritis and Rheumatism . 2001